Last year, Kalispell, Mont.-based Expesicor and Novoron Bioscience of San Diego began working together on a compound for the treatment of neurodegenerative disorders like Alzheimer’s disease. They’ve since co-developed a compound that is in preclinical testing.
Expesicor has considerable experience in drug development for neurological disorders and has developed proprietary therapeutics, imaging probes and drug-screening tools for epilepsy, neurodegenerative disorders, depression, autism and other brain disorders.
Novoron has implemented a novel approach to restoring the regenerative capacity of the brain and spinal cord, and is advancing its channel of biologic therapeutics for the treatment of multiple sclerosis and spinal cord injury.
More articles on biologics:
4 benefits of stem cells in orthopedics from Dr. Jeffrey Carroll
4 trends in spinal fusion market growth, to reach $58.2B by 2025
Spinal fusion costs associated with staph infection: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
